Drugs Containing Excipient (Inactive Ingredient) SODIUM SULFATE

« Back to Dashboard

Branded drugs containing SODIUM SULFATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	TOBREX	tobramycin	0065-0643	SODIUM SULFATE
Alcon Laboratories Inc	TOBRADEX	tobramycin and dexamethasone	0065-0647	SODIUM SULFATE
Alcon Laboratories Inc	TOBRADEX ST	tobramycin / dexamethasone	0065-0652	SODIUM SULFATE
Novartis Pharmaceuticals Corporation	TOBRADEX	tobramycin and dexamethasone	0078-0953	SODIUM SULFATE
STAT Rx USA LLC	TOBRADEX	tobramycin and dexamethasone	16590-223	SODIUM SULFATE
Rebel Distributors Corp	TOBRADEX	tobramycin and dexamethasone	21695-203	SODIUM SULFATE

Generic drugs containing SODIUM SULFATE excipient

Company	Ingredient	NDC	Excipient
Alcon Laboratories Inc	tobramycin	0065-0643	SODIUM SULFATE
Alcon Laboratories Inc	tobramycin and dexamethasone	0065-0647	SODIUM SULFATE
Alcon Laboratories Inc	tobramycin / dexamethasone	0065-0652	SODIUM SULFATE
Novartis Pharmaceuticals Corporation	tobramycin and dexamethasone	0078-0953	SODIUM SULFATE
Henry Schein Inc	tobramycin	0404-7196	SODIUM SULFATE
Padagis US LLC	tobramycin and dexamethasone	0574-4031	SODIUM SULFATE

Sodium Sulfate Excipient Market Dynamics and Financial Trajectory

Last updated: October 29, 2026

Sodium sulfate is a low-cost, high-volume inorganic salt with pharmaceutical applications that represent a small share of global demand. Its financial trajectory is driven primarily by commodity production, pulp and paper consumption, detergents, glass, mining, energy costs, and pharmaceutical-grade qualification. Public companies generally do not disclose sodium sulfate revenue separately, so the pharmaceutical excipient market cannot be valued reliably from audited segment data.

What is sodium sulfate used for in pharmaceutical formulations?

Sodium sulfate is used in pharmaceutical products mainly as an osmotic ingredient, electrolyte, processing aid, or formulation component. Its role depends on the product and concentration.

Pharmaceutical applications

Application	Role of sodium sulfate	Commercial relevance
Bowel-preparation products	Osmotic sulfate salt and active ingredient	High within the sulfate-laxative niche
Oral electrolyte products	Sodium and sulfate source	Limited
Solid-dose formulations	Functional excipient or processing component where permitted	Niche
Pharmaceutical manufacturing	Process salt, pH or ionic-strength adjustment	Contract and API manufacturing demand
Analytical and laboratory use	Reagent or drying agent	Adjacent, not strictly excipient demand

Sodium sulfate should not be confused with sodium lauryl sulfate, which is a surfactant and a separate pharmaceutical excipient. It also differs from sodium sulfite, sodium bisulfate, and sodium metabisulfite.

The strongest pharmaceutical association is with sulfate-based bowel preparations. Products such as SUPREP Bowel Prep Kit contain sodium sulfate, potassium sulfate, and magnesium sulfate as active osmotic ingredients rather than as passive excipients. The FDA-approved labeling identifies the product as an oral solution for colon cleansing before colonoscopy. [1]

How large is the sodium sulfate pharmaceutical excipient market?

No authoritative public source reports a standalone global market value for pharmaceutical-grade sodium sulfate. Market reports typically combine sodium sulfate with broader inorganic salts, pharmaceutical excipients, laxative products, or specialty chemicals.

A defensible market view is therefore based on segmentation:

1. Commodity sodium sulfate production.
2. Pharmaceutical-grade material.
3. Sodium sulfate used in finished drug products.
4. Sulfate-based bowel-preparation products.
5. Manufacturing and analytical applications.

Pharmaceutical demand is small compared with industrial consumption. Sodium sulfate is widely used in kraft pulping, detergents, glass, textiles, and chemical processing. The U.S. Geological Survey identifies sodium sulfate as an industrial mineral with demand tied to multiple non-pharmaceutical sectors. [2]

Market structure

Segment	Demand driver	Pricing profile	Competitive intensity
Industrial sodium sulfate	Pulp, detergents, glass, textiles	Commodity	High
Technical grade	Chemical processing and manufacturing	Low to moderate	High
Pharmaceutical grade	Purity, traceability, GMP controls	Premium to commodity	Moderate
Finished bowel-prep products	FDA approval, branded formulations, generic competition	Product-specific	Moderate to high
Custom pharmaceutical supply	Qualification, documentation, continuity	Contract pricing	Moderate

The pharmaceutical excipient market is likely measured in a fraction of the broader sodium sulfate industry by volume. Its value share is higher because pharmaceutical-grade material requires tighter specifications, controlled contamination limits, validated analytical methods, change-control systems, and documented supply continuity.

What is the financial trajectory for sodium sulfate suppliers?

The financial trajectory for sodium sulfate suppliers is primarily cyclical and cost-driven rather than innovation-driven. Revenue growth depends on volume, contract pricing, energy costs, freight, feedstock availability, and the mix between commodity and qualified grades.

Key financial drivers

Industrial demand

Pulp and paper remains a major end use for sodium sulfate. A decline in paper production can reduce demand for virgin sodium sulfate, while recycled paper substitution and mill closures can alter regional purchasing patterns. Detergent demand also affects consumption, although sodium sulfate has faced substitution and formulation changes in some detergent markets. [2]

Byproduct and natural-source economics

Sodium sulfate is produced from natural deposits and as a byproduct of chemical processes. Byproduct producers can have lower marginal costs when sodium sulfate is recovered from an existing process. Natural-source producers are more exposed to mining, evaporation, water, energy, and logistics costs.

This creates a fragmented cost curve. A low-cost byproduct producer can pressure prices even when pharmaceutical qualification limits the number of suppliers available to a drug manufacturer.

Pharmaceutical-grade premiums

Pharmaceutical-grade sodium sulfate can command a premium over industrial material. The premium compensates for:

• GMP manufacturing and quality systems.
• Pharmacopoeial testing.
• Elemental impurity controls.
• Microbial and particulate specifications.
• Lot traceability.
• Stability and packaging controls.
• Supplier audits and change notification.
• Regulatory documentation.

The premium is constrained by the chemical simplicity of sodium sulfate. Buyers can qualify alternative sources more readily than they can for complex excipients, polymers, lipids, or biologically derived materials.

Logistics

Sodium sulfate is dense and inexpensive relative to its transport weight. Freight can represent a significant portion of delivered cost, particularly for international shipments. Regional production and local warehousing can therefore be more important than nominal ex-works price.

Financial outlook by time horizon

Period	Expected market condition	Financial implication
Near term	Stable pharmaceutical demand; volatile industrial demand	Margin depends on contracts and logistics
Medium term	Continued use in bowel preparations and manufacturing	Modest volume growth, limited pricing power
Longer term	Qualification barriers remain, but substitution risk persists	Stable niche revenue rather than high-growth expansion

The pharmaceutical segment should have lower volume volatility than industrial markets, but it is unlikely to generate the high margins associated with protected drug substances or differentiated delivery technologies.

Which companies supply pharmaceutical-grade sodium sulfate?

The supplier landscape includes specialty chemical companies, mineral producers, regional manufacturers, and distributors. Public disclosures rarely identify pharmaceutical-grade sodium sulfate revenue by product or customer.

Supplier selection usually depends on:

• Pharmacopoeial compliance.
• Manufacturing site and country.
• DMF or equivalent regulatory support.
• Audit history.
• Batch consistency.
• Packaging and particle-size control.
• Capacity reservation.
• Dual-source feasibility.

Large industrial suppliers may offer lower unit costs but may not have a pharmaceutical-grade documentation package. Specialty suppliers may provide stronger regulatory support but at higher prices and lower available volume.

A pharmaceutical manufacturer normally evaluates sodium sulfate as a qualified raw material rather than as a strategic innovation asset. Once approved, the material can remain in the formulation for many years, but changing suppliers may require comparability testing, regulatory notification, or prior approval depending on the product and jurisdiction.

What FDA regulatory status applies to sodium sulfate?

Sodium sulfate does not have a single FDA status that applies to every pharmaceutical use. The regulatory treatment depends on whether it is an active ingredient, an inactive ingredient, or a manufacturing material.

Active ingredient status

In sulfate-based bowel preparations, sodium sulfate is an active ingredient. SUPREP Bowel Prep Kit is an FDA-approved prescription product containing sodium sulfate, potassium sulfate, and magnesium sulfate. [1]

Inactive ingredient status

For excipient use, manufacturers must evaluate the FDA Inactive Ingredient Database, applicable monographs, product-specific precedent, and the proposed route and dosage. An inactive-ingredient listing does not create blanket approval for all formulations or concentrations. [3]

Pharmacopoeial standards

Sodium sulfate may be subject to compendial requirements under the United States Pharmacopeia-National Formulary or other recognized pharmacopoeias. The relevant specification can cover identity, assay, impurities, water content, heavy metals or elemental impurities, and other quality attributes. [4]

The European Union applies a similar product-specific approach through European Pharmacopoeia requirements, excipient GMP expectations, and marketing-authorization documentation. [5]

What patents protect sodium sulfate formulations?

The sodium sulfate molecule is an old, simple inorganic compound and is not the source of meaningful composition-of-matter exclusivity. Patent protection generally attaches to a formulation, dosage form, combination, manufacturing process, packaging system, or method of use.

Formulation patents

Potentially protectable elements include:

• Multi-sulfate bowel-preparation compositions.
• Reduced-volume oral solutions.
• Solid tablets containing sodium sulfate.
• Taste-masking systems.
• Effervescent or rapidly dissolving dosage forms.
• Specific electrolyte ratios.
• Stabilized or concentrated formulations.
• Packaging configurations that preserve product quality.

SUTAB is an example of a tablet-based bowel-preparation product containing sodium sulfate, magnesium sulfate, and potassium chloride. Its commercial protection depends on the approved product, patents listed for the product, regulatory exclusivity, and litigation outcomes rather than on sodium sulfate itself. [6]

Method-of-use patents

Method claims may cover:

• Colon cleansing before colonoscopy.
• Split-dose administration.
• Specific dosing intervals.
• Use in patients with defined clinical characteristics.
• Reduced fluid-volume regimens.

Method-of-use claims can create launch risk for a generic even when the underlying sodium sulfate composition is old. Their enforceability depends on claim scope, labeling, induced-infringement evidence, and the proposed generic label.

Manufacturing patents

Manufacturing claims may address purification, crystallization, particle-size control, drying, recovery from industrial streams, or impurity reduction. These patents are more relevant to suppliers than to finished-dose manufacturers. They generally do not create a broad barrier to obtaining sodium sulfate from alternative sources.

What is the Orange Book status of sodium sulfate products?

Sodium sulfate itself is not an Orange Book-listed drug because the Orange Book lists approved drug products and associated patent and exclusivity information, not standalone excipients. [7]

Finished prescription bowel-preparation products containing sodium sulfate may appear in FDA product and patent databases. The relevant analysis must be performed at the product level:

Question	Correct scope
Is sodium sulfate in the Orange Book?	No, not as a standalone excipient
Can a sodium sulfate drug product be listed?	Yes, if it is an FDA-approved finished drug
Can patents cover the product?	Yes, through formulation, use, dosage form, or other claims
Can a generic file Paragraph IV?	Yes, if the reference product has listed patents and the ANDA applicant challenges them
Does a sodium sulfate supplier face Paragraph IV risk?	Usually no; the risk is concentrated at the finished-product applicant level

When do sodium sulfate bowel-preparation products lose exclusivity?

Exclusivity is product-specific. There is no single loss-of-exclusivity date for sodium sulfate.

For each reference product, the relevant dates include:

1. FDA approval date.
2. New chemical entity or other statutory exclusivity, if applicable.
3. Patent expiration dates.
4. Pediatric exclusivity extensions.
5. Patent-term adjustments or extensions.
6. Settlement restrictions.
7. Generic approval timing.
8. Regulatory requirements for labeling and dosage-form equivalence.

A sodium sulfate product may face generic entry after statutory exclusivity expires, subject to remaining patents and FDA approval requirements. Patent expiry alone does not guarantee immediate generic launch.

Which companies are challenging sodium sulfate bowel-preparation products?

Generic and specialty pharmaceutical companies may challenge branded bowel-preparation products through ANDAs, Paragraph IV certifications, or non-infringement and invalidity positions. The public risk assessment must be conducted product by product using FDA Orange Book records, FDA approval data, and federal court dockets.

The main competitive categories are:

• Generic oral sulfate solution manufacturers.
• Generic tablet-based bowel-preparation manufacturers.
• Branded gastrointestinal companies.
• Contract manufacturers with electrolyte and oral-solution capabilities.
• Firms pursuing lower-volume or lower-fluid regimens.

A supplier of sodium sulfate can benefit from generic entry because total finished-product demand may expand. It can also face price pressure if generic manufacturers conduct competitive bidding or qualify lower-cost international sources.

What patent litigation affects sodium sulfate products?

Patent litigation is generally concentrated on branded bowel-preparation products rather than on sodium sulfate as an excipient. The most relevant disputes concern:

• Tablet composition.
• Sulfate ratios.
• Dosing schedules.
• Low-volume administration.
• Labeling and method-of-use claims.
• Formulation stability.
• Patent validity and obviousness.
• ANDA filing dates.

A sodium sulfate raw-material supplier is usually several steps removed from this litigation. Its direct exposure increases only if the supplier owns formulation patents, supplies a protected product under license, or is named in a manufacturing or trade-secret dispute.

Are licensing deals important in the sodium sulfate market?

Licensing is more important for finished bowel-preparation products than for sodium sulfate supply. The raw material is generally purchased through supply agreements rather than licensed under patent rights.

Commercial agreements may include:

• Long-term supply contracts.
• Minimum-volume commitments.
• Dual-source arrangements.
• Territory restrictions.
• Technology licenses for tablet or solution formulations.
• Co-development agreements.
• Contract manufacturing arrangements.
• Regulatory-support obligations.

The value of a sodium sulfate supply contract is determined by continuity, qualification status, and switching cost. The value of a finished-product license depends on FDA approval, patent life, sales potential, and generic exposure.

How strong is the patent estate for sodium sulfate?

The patent estate is weak for the molecule and potentially meaningful for specific finished products.

Asset	Patent strength
Sodium sulfate molecule	Very low
Generic pharmaceutical-grade material	Low
Purification or crystallization process	Low to moderate
Sulfate bowel-prep formulation	Moderate
Tablet or low-volume dosage form	Moderate to strong, depending on claims
Dosing method	Variable
Packaging and stability system	Variable
Approved branded product	Depends on patent and regulatory exclusivity

The primary barriers are regulatory qualification, manufacturing consistency, customer switching costs, and supply reliability. They are not composition-of-matter barriers.

What generic entry risks exist for sodium sulfate products?

Generic entry risk is highest for products with:

• Expired or weak formulation patents.
• Straightforward oral solutions.
• Established active-ingredient specifications.
• Multiple qualified manufacturers.
• No meaningful clinical differentiation.
• Broad generic substitution potential.

Risk is lower for products with:

• Tablet technology.
• Complex dosing regimens.
• Narrow method-of-use claims.
• Difficult taste-masking requirements.
• Manufacturing-sensitive particle characteristics.
• Limited supplier qualification.
• Strong settlement protections.

Generic entry can reduce branded-product prices while increasing demand for raw sodium sulfate. The net effect on excipient suppliers depends on whether the market shifts toward lower-cost commodity material or toward more qualified pharmaceutical-grade supply.

How does sodium sulfate compare with competing bowel-preparation ingredients?

Ingredient or product class	Commercial role	Patent exposure	Supply risk
Sodium sulfate combinations	Osmotic bowel preparation	Moderate at formulation level	Low to moderate
Polyethylene glycol-electrolyte solutions	Large-volume bowel preparation	Low to moderate	Low
Sodium phosphate products	Osmotic bowel preparation	Generally mature	Regulatory and safety constraints
Magnesium citrate products	Osmotic laxative	Low to moderate	Low
Tablet-based sulfate combinations	Lower-volume bowel preparation	Higher formulation exposure	Moderate

Sodium sulfate has a favorable raw-material profile because it is inexpensive, stable, and widely available. Finished products compete on tolerability, required fluid volume, dosing convenience, safety, and physician preference.

What manufacturing and geographic barriers affect the market?

Geographic coverage matters because sodium sulfate is heavy, low-value, and subject to freight economics. Regional supply can be more competitive than global shipment.

Key geographic factors

• North America has established industrial and pharmaceutical distribution channels.
• Europe applies tighter documentation and excipient quality expectations.
• China and India provide substantial chemical manufacturing capacity, but supplier qualification and regulatory documentation vary by site.
• Latin America and other import-dependent markets face greater freight and inventory exposure.
• Local registration, GMP inspection history, and import controls can affect market access.

Manufacturing barriers are modest at the chemical level but higher at the pharmaceutical-quality level. A new supplier may need customer audits, analytical comparability, stability data, change-control commitments, and multiple commercial batches before approval.

What is the revenue exposure for pharmaceutical companies?

For excipient suppliers, sodium sulfate is unlikely to represent a material share of consolidated revenue unless the company specializes in inorganic salts or supplies a large branded bowel-preparation franchise. For finished-product manufacturers, revenue exposure can be meaningful because bowel-preparation products may generate recurring prescription and procedure-related demand.

The commercial risk differs by business model:

Business model	Revenue exposure
Commodity sodium sulfate producer	Broad industrial exposure; pharmaceutical share small
Pharmaceutical-grade supplier	Higher margin, low volume, customer concentration risk
Branded bowel-prep company	Higher product concentration and patent risk
Generic manufacturer	Price-sensitive, volume-driven opportunity
Distributor	Freight, inventory, and supply continuity exposure

No public financial dataset reliably isolates pharmaceutical-grade sodium sulfate revenue. Company-level analysis must therefore use product disclosures, customer contracts, shipment data, and segment commentary rather than reported sodium sulfate sales.

Key Takeaways

• Sodium sulfate is a mature, low-cost inorganic salt with a small pharmaceutical share of total demand.
• Its main pharmaceutical value is in sulfate-based bowel-preparation products and selected formulation or manufacturing uses.
• The molecule has little standalone patent protection.
• Product-level patents can protect tablets, low-volume formulations, dosing methods, and stability systems.
• Sodium sulfate is not independently listed in the Orange Book; finished drug products may be listed.
• Pharmaceutical-grade premiums arise from GMP controls, documentation, testing, and supply qualification.
• Financial performance is driven more by industrial demand, production economics, freight, and customer qualification than by pharmaceutical innovation.
• Generic entry can pressure finished-product prices while expanding demand for qualified raw material.
• Public companies generally do not disclose sodium sulfate pharmaceutical revenue separately.
• The strongest competitive barriers are regulatory qualification and supply reliability, not molecular exclusivity.

FAQs

Is sodium sulfate an active pharmaceutical ingredient or an excipient?

It can be either. In sulfate-based bowel preparations, sodium sulfate is an active ingredient. In other pharmaceutical formulations or manufacturing processes, it may be used as an excipient or process material.

Is pharmaceutical-grade sodium sulfate interchangeable with industrial sodium sulfate?

No. Pharmaceutical use requires documented specifications, traceability, impurity controls, quality-system oversight, and customer qualification. Industrial grade cannot be substituted automatically.

Does sodium sulfate have a Drug Master File?

A supplier may maintain a DMF or equivalent regulatory package, but the existence and scope of a specific DMF are supplier-specific and are not inherent to sodium sulfate.

Can a generic company avoid sodium sulfate patents by using another sulfate salt?

Possibly, but the alternative must satisfy formulation, safety, efficacy, labeling, and regulatory requirements. A change in salt can create new formulation and bioequivalence issues.

Is sodium sulfate exposed to biosimilar competition?

No. Sodium sulfate is a small-molecule inorganic salt, not a biologic. Biosimilar pathways do not apply. Competition arises from generic drugs, alternative bowel-preparation formulations, and competing excipient suppliers.

References

1. U.S. Food and Drug Administration. (2023). SUPREP Bowel Prep Kit prescribing information. https://www.accessdata.fda.gov
2. U.S. Geological Survey. (2024). Mineral commodity summaries 2024: Sodium sulfate. https://pubs.usgs.gov/periodicals/mcs2024/mcs2024-sodium-sulfate.pdf
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=inactiveingredient
4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. https://www.usp.org
5. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. https://www.edqm.eu
6. Sebela Pharmaceuticals. (2023). SUTAB prescribing information. https://www.accessdata.fda.gov
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files